SG11201707345VA - Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection - Google Patents
Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infectionInfo
- Publication number
- SG11201707345VA SG11201707345VA SG11201707345VA SG11201707345VA SG11201707345VA SG 11201707345V A SG11201707345V A SG 11201707345VA SG 11201707345V A SG11201707345V A SG 11201707345VA SG 11201707345V A SG11201707345V A SG 11201707345VA SG 11201707345V A SG11201707345V A SG 11201707345VA
- Authority
- SG
- Singapore
- Prior art keywords
- agent
- lysosomotropic
- treatment
- combination
- bacterial infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15158880 | 2015-03-12 | ||
| PCT/EP2016/055076 WO2016142445A2 (en) | 2015-03-12 | 2016-03-10 | A method of treatment of a bacterial infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707345VA true SG11201707345VA (en) | 2017-10-30 |
Family
ID=52648929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707345VA SG11201707345VA (en) | 2015-03-12 | 2016-03-10 | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11690899B2 (enExample) |
| EP (1) | EP3268023B1 (enExample) |
| JP (1) | JP2018509415A (enExample) |
| KR (1) | KR102683284B1 (enExample) |
| CN (1) | CN107580503B (enExample) |
| AU (1) | AU2016231141B2 (enExample) |
| IL (1) | IL254457B (enExample) |
| SG (1) | SG11201707345VA (enExample) |
| WO (1) | WO2016142445A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11427812B2 (en) * | 2016-11-18 | 2022-08-30 | Lysando Ag | Antimicrobial agents against Staphylococcus aureus |
| WO2019068875A1 (en) | 2017-10-06 | 2019-04-11 | Micreos Human Health B.V. | TREATMENT OF A HEALTH CONDITION ASSOCIATED WITH INFECTION BY ONCOGENIC BACTERIA |
| EP3688011A4 (en) * | 2017-10-25 | 2021-11-24 | The Administrators Of The Tulane Educational Fund | PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE |
| US11149068B2 (en) | 2018-01-05 | 2021-10-19 | The Administrator Of The Tulane Educational Fund | Pore-forming peptides and uses thereof |
| JP7131803B2 (ja) * | 2018-05-15 | 2022-09-06 | 学校法人大阪医科薬科大学 | Gb3蓄積起因性疾患の予防又は治療剤 |
| MX2020014006A (es) * | 2018-06-29 | 2021-05-27 | Res Inst Nationwide Childrens Hospital | Composiciones y métodos para mediar la eps. |
| CN109350618B (zh) * | 2018-12-10 | 2021-09-28 | 山东农业大学 | 自噬调节剂在消除牛乳腺上皮细胞内金黄色葡萄球菌中的应用 |
| CN120136980A (zh) * | 2019-05-08 | 2025-06-13 | 生物技术公司 | 新的加德纳菌内溶素及其用途 |
| GB201906653D0 (en) * | 2019-05-10 | 2019-06-26 | Cc Biotech Ltd | Polypeptides for treatment of bacterial infections |
| CA3171721A1 (en) | 2020-03-19 | 2021-09-23 | Fritz Eichenseher | A stabilized protein of interest |
| WO2024020533A1 (en) * | 2022-07-22 | 2024-01-25 | Endolytix Technology, Inc. | Immunogenic compositions for treating or preventing actinomycetia infections |
| AU2023408646A1 (en) * | 2022-12-23 | 2025-07-31 | Micreos Pharmaceuticals Ag | A chimeric endolysin polypeptide |
| CN120513297A (zh) * | 2023-01-09 | 2025-08-19 | 华中农业大学 | 细菌裂解酶及其应用 |
| WO2024200687A1 (en) * | 2023-03-29 | 2024-10-03 | Universiteit Gent | Chimeric endolysins with activity against streptococci and staphylococci |
| WO2024241070A1 (en) | 2023-05-22 | 2024-11-28 | L'oreal | Cosmetic composition comprising an endolysin and a polyvinyl alcohol |
| FR3149202B1 (fr) | 2023-06-02 | 2026-04-10 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile. |
| FR3149209B1 (fr) | 2023-06-02 | 2026-04-03 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique |
| FR3149204B1 (fr) | 2023-06-02 | 2026-02-13 | Oreal | Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate |
| FR3149206B1 (fr) | 2023-06-02 | 2026-03-13 | Oreal | Composition cosmétique aqueuse comprenant une endolysine et du tréhalose |
| FR3149205B1 (fr) | 2023-06-02 | 2026-04-24 | Oreal | Composition cosmétique comprenant une endolysine et un agent de charge organique |
| FR3152395A1 (fr) | 2023-08-28 | 2025-03-07 | L'oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone |
| EP4719330A1 (en) | 2023-06-02 | 2026-04-08 | L'oreal | Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol |
| FR3149208B1 (fr) | 2023-06-02 | 2026-03-20 | Oreal | Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane |
| FR3149207B1 (fr) | 2023-06-02 | 2026-03-13 | Oreal | Composition cosmétique comprenant une endolysine et un composé de formule (I) |
| FR3149203B1 (fr) | 2023-06-02 | 2026-03-13 | Oreal | Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane |
| FR3152394B1 (fr) | 2023-08-28 | 2026-04-24 | Oreal | Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe |
| FR3152396A1 (fr) | 2023-08-28 | 2025-03-07 | L'oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane |
| FR3152393B1 (fr) | 2023-08-28 | 2026-04-24 | Oreal | Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale |
| WO2025093666A1 (en) | 2023-11-01 | 2025-05-08 | University Of Copenhagen | Treatment of lymphoma |
| WO2026052743A1 (en) | 2024-09-04 | 2026-03-12 | Micreos Human Health B.V. | Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020187136A1 (en) * | 2000-04-28 | 2002-12-12 | Lawrence Loomis | Use of bacterial phage associated lysing enzymes for treating various illnesses |
| US20040023897A1 (en) * | 2001-11-13 | 2004-02-05 | Caplan Michael J. | Methods for preventing or treating disease mediated by toxin-secreting bacteria |
| KR100759988B1 (ko) * | 2006-08-04 | 2007-09-19 | 주식회사 인트론바이오테크놀로지 | 황색포도상구균에 특이적인 항균 단백질 |
| US20100028334A1 (en) * | 2006-12-15 | 2010-02-04 | Trustees Of Boston University | Compositions and methods to potentiate colistin activity |
| US8383102B2 (en) | 2009-05-21 | 2013-02-26 | The United States Of America As Represented By The Secretary Of Agriculture | Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens |
| SG178440A1 (en) | 2009-08-24 | 2012-04-27 | Univ Leuven Kath | New endolysin obpgplys |
| EP2338916A1 (en) | 2009-12-23 | 2011-06-29 | Hyglos Invest GmbH | Chimeric polypeptides and their use in bacterial decoloniation |
| US20140120074A1 (en) | 2011-04-27 | 2014-05-01 | Lysando Ag | Antimicrobial agents |
| CN103703127A (zh) | 2011-05-04 | 2014-04-02 | 迈克瑞欧斯人体健康有限公司 | 一种多肽 |
| SG11201407284TA (en) | 2012-05-07 | 2014-12-30 | Micreos Human Health Bv | Polypeptide mixes with antibacterial activity |
| KR20210121313A (ko) * | 2012-05-09 | 2021-10-07 | 콘트라펙트 코포레이션 | 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 |
| US9603909B2 (en) * | 2012-05-29 | 2017-03-28 | Intron Biotechnology, Inc. | Composition capable of improving stability of bacteriophage lysin proteins |
| US9206411B2 (en) * | 2012-06-13 | 2015-12-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Staphylococcal Phage2638A endolysin amidase domain is lytic for Staphylococcus aureus |
| EP2679677A1 (en) | 2012-06-29 | 2014-01-01 | Lysando Aktiengesellschaft | Composition for use in Mycobacteria therapy |
| US20160097044A1 (en) | 2014-10-01 | 2016-04-07 | The United States Of America, As Represented By The Secretary Of Agriculture | Antimicrobial Enzyme Fusions Reduce Resistance and Kill Intracellular Staphylococcus aureus |
-
2016
- 2016-03-10 SG SG11201707345VA patent/SG11201707345VA/en unknown
- 2016-03-10 EP EP16709389.7A patent/EP3268023B1/en active Active
- 2016-03-10 AU AU2016231141A patent/AU2016231141B2/en active Active
- 2016-03-10 WO PCT/EP2016/055076 patent/WO2016142445A2/en not_active Ceased
- 2016-03-10 US US15/557,296 patent/US11690899B2/en active Active
- 2016-03-10 CN CN201680026953.2A patent/CN107580503B/zh active Active
- 2016-03-10 JP JP2017547980A patent/JP2018509415A/ja active Pending
- 2016-03-10 KR KR1020177028879A patent/KR102683284B1/ko active Active
-
2017
- 2017-09-12 IL IL254457A patent/IL254457B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170132201A (ko) | 2017-12-01 |
| AU2016231141B2 (en) | 2022-03-03 |
| KR102683284B1 (ko) | 2024-07-10 |
| CA2979873A1 (en) | 2016-09-15 |
| US20180271952A1 (en) | 2018-09-27 |
| CN107580503A (zh) | 2018-01-12 |
| EP3268023B1 (en) | 2021-08-18 |
| IL254457A0 (en) | 2017-11-30 |
| JP2018509415A (ja) | 2018-04-05 |
| BR112017019413A2 (pt) | 2018-05-02 |
| AU2016231141A1 (en) | 2017-09-28 |
| WO2016142445A2 (en) | 2016-09-15 |
| IL254457B (en) | 2020-03-31 |
| HK1249033A1 (en) | 2018-10-26 |
| WO2016142445A3 (en) | 2016-11-10 |
| CN107580503B (zh) | 2021-07-09 |
| EP3268023A2 (en) | 2018-01-17 |
| US11690899B2 (en) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254457A0 (en) | A combination of a bactericide and a lysosomotropic alkaline agent for the treatment of bacterial infection | |
| IL270695A (en) | catheter | |
| ZA201802719B (en) | Treatment compositions providing an antimicrobial benefit | |
| ZA201703245B (en) | Combination therapy for treatment of resistant bacterial infections | |
| SG11201608719YA (en) | Catheter tubing with extraluminal antimicrobial coating | |
| SG11201606247QA (en) | Antimicrobial inserts for medical devices | |
| CA186425S (en) | Catheter | |
| ZA201800189B (en) | Substituted phenyloxazolidinones for antimicrobial therapy | |
| SG11202001205PA (en) | Anti-occlusion catheter | |
| GB201813876D0 (en) | Treatment | |
| PL3497095T3 (pl) | Związki chelatujące cynk do stosowania w leczeniu zakażenia bakteryjnego | |
| PL3448992T3 (pl) | Środki przeciwdrobnoustrojowe na bakterie Salmonella | |
| ZA201801134B (en) | Hydroxytriazine compound and medical use thereof | |
| GB201800546D0 (en) | Treatment | |
| SG11201808307QA (en) | Multi-diameter cannula | |
| IL253878A0 (en) | An effective substance for the treatment of respiratory inflammation | |
| GB201718985D0 (en) | Treatment | |
| GB2558090B (en) | Prevention and treatment for microbial infections | |
| CA186424S (en) | Catheter | |
| GB201807050D0 (en) | Medical uses | |
| GB201717551D0 (en) | Antimicrobial agents | |
| GB201708650D0 (en) | Combination therapy for bacterial infection | |
| GB201814905D0 (en) | Treatment | |
| GB201803494D0 (en) | Treatment regime | |
| GB201711677D0 (en) | Combination treatment |